Daxor Corp
DXR
Company Profile
Business description
Daxor Corp is a medical instrumentation and biotechnology company focused on blood volume measurement. The company develops and markets the BVA-100 (Blood Volume Analyzer), the first diagnostic blood test cleared by the FDA offers unmatched, real-time, precise data via its rapid, hand-held, lab-based system. The company operates as a single business segment centered on the development, commercialization, and support of its proprietary blood volume analysis technology used by healthcare providers.
Contact
107 Meco Lane
Oak RidgeTN37830
USAT: +1 212 330-8500
Sector
Healthcare
Stock type
Defensive
Industry
Medical Instruments & Supplies
Fiscal Year End
31 December 2026
Employees
750
Stocks News & Analysis
stocks
Two cheap wide moat ASX shares
These shares are trading at a discount to our fair value discount and have sustainable competitive advantages.
stocks
Anthropic: Are the shares undervalued given the IPO pricing range?
There may be meaningful upside as Anthropic is pricing its stock as a reflection of current sentiment, not the company’s fundamentals.
stocks
Valuation looks stretched for ASX healthcare share
Strong fundamentals meet a demanding valuation.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 9,274.20 | 6.40 | 0.07% |
| CAC 40 | 8,361.36 | 28.49 | 0.34% |
| DAX 40 | 26,771.88 | 109.11 | 0.41% |
| Dow JONES (US) | 52,657.61 | 171.12 | 0.33% |
| FTSE 100 | 10,863.09 | 27.62 | 0.25% |
| HKSE | 24,008.55 | 307.37 | -1.26% |
| NASDAQ | 25,488.72 | 22.53 | 0.09% |
| Nikkei 225 | 60,819.36 | 359.78 | 0.60% |
| NZX 50 Index | 14,259.23 | 91.82 | 0.65% |
| S&P 500 | 7,632.58 | 13.20 | 0.17% |
| S&P/ASX 200 | 9,146.80 | 17.80 | 0.19% |
| SSE Composite Index | 3,655.83 | 24.81 | -0.67% |